FTC Hits Edwards Lifesciences with $12M Penalty for Antitrust Reporting Violations
EW sits 27% above its 52-week low of $72.3 on light trading volume (0.2× avg).
Summary
The FTC secured $12 million in penalties from Edwards Lifesciences for allegedly structuring its acquisition of JC Medical to avoid mandatory antitrust review under the HSR Act. The settlement resolves charges that Edwards and Genesis MedTech deliberately bypassed notification and waiting period requirements. Edwards will also be subject to additional terms including prior notice requirements. This is a significant regulatory rebuke for a company already facing multi-billion dollar IRS tax disputes, as disclosed in its May 10-Q. The penalty itself is modest relative to Edwards' $53B market cap, but the violation finding could invite heightened FTC scrutiny on future deals and signals aggressive antitrust enforcement in the medical device space.
At the time of this announcement, EW was trading at $91.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $52.9B. The 52-week trading range was $72.30 to $96.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.